None listed
Conditions
Brief summary
This study will prospectively assess the clinical effects of SGLT2 inhibitors in people with type 2 diabetes who attend RMH diabetes clinic. The primary aim is to determine their effect on HbA1c after 3 months of therapy. We hypothesise that people who take these drugs will on average lower their HbA1c by 0.5%.
Interventions
Oral SGLT2 inhibitor, including dapagliflozin, empagliflozin and canagliflozin. The dose and frequency will be determined by the treating clinician as per standard care and will not be defined as part of this study. Each patient will be followed with blood tests and questionnaires at 3 and 6 months after starting SGLT2 inhibitor therapy.
Sponsors
John Wentworth
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Type 2 diabetes according to ADA criteria No planned changes to glucose-lowering or blood pressure-lowering therapy Due to commence SGLT2 inhibitor therapy Willing to comply with therapy, tests and clinical follow-up Deemed unlikely to require adjustment of blood pressure- or lipid-lowering medication over the next 6 months
Exclusion criteria
Unable to provide informed consent Use of SGLT2 inhibitor in previous fortnight Contra-indication to SGLT2 inhibitor therapy, including stage 4 or 5 chronic kidney disease (eGFR<30) and history of genitourinary infection Presence of a comorbidity that, in the investigators’ opinion, would impair compliance with SGLT2 inhibitor therapy or the study protocol Pregnancy or desire for pregnancy within the next year Urinary frequency that may prevent abstinence from urination for the 5-hour period before clinic visits
Outcome results
None listed